Streptochinasi nell' Infarto Myocardico (GISSI-2)/International Study Group,19 Third International Study of Infarct Survival (ISIS-3),3 and other trials",20-23 that compared the effects of different biologically active thrombolytic agents with each other, as opposed to the earlier placebo-controlled trials. Few would dispute that a relatively clot-selective agent such as tissue-type plasminogen activator (t-PA) lyses clots more rapidly than do the nonselective agents such as streptokinase, when 90-minute recanalization rates are the benchmark for comparison, although somewhat later patency rates (3 to 24 hours) essentially are equivalent.7"15'24-27 Yet, this difference does not appear to be translated into a From
Current Perspectives
Thrombolysis and Myocardial Salvage Results of Clinical Trials and the Animal Paradigm-Paradoxic or Predictable?
Bernard J. Gersh, MB,ChB, DPhil, and Jeffrey L. Anderson, MD T he era of acute reperfusion has witnessed a dramatic change in the management of acute myocardial infarction in an expanding group of patients who are considered eligible for this form of therapy.1-3 The rationale, based on experimental data obtained in animal models, is logical,4-6 and the results of carefully controlled randomized trials have been shown to meet expectations.1,7-12 The restoration of coronary blood flow does reduce mortality, and the earlier this is achieved, the greater is the benefit. Myocardial salvage, although difficult to quantify, is the logical explanation.
Implications of the Randomized Trials Nonetheless, although numerous randomized trials systematically have provided answers to the many questions posed in the 1970s and 1980s, they also have raised new issues. The discrepancy between the impressive reduction in mortality and the relative lack of effect on left ventricular function has been a source of debate and questions the traditionally accepted relationship between coronary artery patency, myocardial salvage, and ventricular function.A4,5,3-17 Imprecision in the measurement of salvage is one explanation, as is speculative but intriguing evidence implicating an independent beneficial effect of an open infarct-related artery on survivalthe "open-artery concept."113-'7 The animal paradigm of early reperfusion and myocardial salvage has especially undergone scrutiny in the light of data provided by the Thrombolysis in Myocardial Infarction (TIMI) trial,18 Gruppo Italiano per lo Studio Della difference in mortality,3"9 and there is little23 or no difference12"18 in ventricular function.
The implications of these trials are profound and far reaching.'5 Is the more rapid achievement of early (90 minutes) patency by one agent compared with another of little clinical relevance? Is research into a new generation of thrombolytic agents, which achieve even more rapid and complete patency, still warranted? Should we be devoting our attention to the development of strategies such as prehospital thrombolytic therapy? Are the levels of anticoagulation aimed at preventing reocclusion in ISIS-3 and GISSI-2 adequate? Many would consider the method and dosage suboptimal, particularly in patients receiving t-PA, but the risk-tobenefit ratio of intravenous heparin therapy warrants further analysis. [28] [29] [30] [31] Nonetheless, this is a valid concern, and the issue must be resolved -the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial should settle the question. 24, 25 Potential Explanations: Thrombolysis, Myocardial Salvage, and Reocclusion Thrombolytic Regimens and the Heparin Hypothesis A discrepancy between patency and mortality among agents would be observed if an expected patency differential was not achieved or maintained. In the GISSI-2/ International Study and ISIS-3, heparin was given subcutaneously, and its initiation was delayed by 4 to 12 hours.3"19 The omission of heparin after administration of t-PA has been shown in several studies to lead to significant reductions in patency rates at 1 day or more.28- 31 The differentially higher reocclusion rates after use of t-PA in comparison with streptokinase or anisoylated plasminogen streptokinase activator complex (APSAC) (drugs that are systemically active with longer half-lives and lower reocclusion potential) might act to negate any innate advantage of t-PA. 30 However, four observations argue against a large effect of the omission of intravenous heparin on the mortality results from these trials.'5 First, when aspirin was given immediately with t-PA in doses of 160 mg or more (as in GISSI-2 and ISIS-3), the shortfall in plateau patency rate, compared with that when full-dose intravenous heparin was used, was much more modest (9%).31 Second, among 3240 patients given intravenous heparin, out of protocol, and randomized to t-PA or streptokinase, no differential trend in 5-week mortality favoring t-PA emerged (9.4% versus 9.2%), although no attempt was made to adjust for baseline differences in this nonrandomized comparison.3 Third, reinfarction Days from randomization was observed less frequently after use of t-PA,3 and this finding was unexpected given the higher reocclusion rates with t-PA in prior angiographical studies. 7,15,24'26,27 Fourth, APSAC, which is longer acting and more efficient than streptokinase, does not require early intravenous administration of heparin to maintain near optimal patency rates,32 but it fared no better than streptokinase in the three-way mortality comparison. 3 Despite the key role of heparin in the prevention of reocclusion after thrombolytic therapy, whether the mode and administration of heparin constitute the sole explanation for the lack of difference between thrombolytic agents in the ISIS-3 and GISSI-2 trials is moot. Review of the published data illustrates that mortality rates at 35 days are virtually identical (Fig 1) . One would, therefore, have to postulate that the increased patency rate with t-PA is almost exactly offset by a higher rate of reocclusion with doses of heparin that many believe are subtherapeutic. This is a plausible explanation, but does it account for the remarkable similarity in survival rates with use of the various agents? If this explanation is shown to be inaccurate, then the original hypothesis-that the earlier reperfusion is achieved, the greater is the extent of salvagecould be questioned. This is a perplexing situation, given the ample documentation of the beneficial effects of thrombolytic therapy on mortality.
Discrepancy between 90-minute patency rates and relative mortality benefits could occur if the benefits of therapy were primarily due to other mechanisms, such as a reduction in blood viscosity33 or an effect on metabolism in ischemic myocardium.34 However, relegating patency to a secondary role in thrombolytic therapy would fly in the face of numerous clinical and experimental observations that support the primacy of achieving reperfusion.7,13-17
Measurement of Myocardial Salvage in Patients
The recent ability to document the extent of myocardial salvage in the clinical situation provides a novel perspective from which the established tenets of reperfusion as a means of reducing infarct size can be reexamined (Table 1) 14 21 28 35 provided the opportunity to document the extent of myocardial salvage after acute reperfusion in humans.6,36 Several clinical studies have emphasized the wide variability in the extent of myocardial jeopardy among individual patients, but a recent series from the Mayo Clinic also provided reassuring evidence that both thrombolytic therapy and primary angioplasty do result in salvage of a substantial extent of ischemic but viable myocardium (Fig 2) . 36 The report described 37 patients with anterior (20 patients) and inferior (17 patients) infarctions treated with t-PA or percutaneous transluminal coronary angioplasty approximately 3 hours after the onset of symptoms. In this study, the extent of myocardium at risk included 36% of the left ventricle (substantially more with anterior infarctions), and approximately 44% of the area at risk (16% of the left ventricle) was salvaged; the final infarct size was 20% of the left ventricle (Figs 2 and 3). 36 The time to reperfusion therapy in these studies is consistent with the clinical practice in most recently reported series and clinical trials.
In an attempt to estimate the extent of salvage (after a similar duration of symptoms) using a drug associated with a lower 90-minute patency rate or speed of reperfusion than has been documented with t-PA, we have developed a theoretical analysis that uses several potentially simplistic assumptions. A major assumption implies that the speed of reperfusion and its impact on 90-minute patency are correlated with the extent of salvage, albeit without any degree of precision. Nonetheless, a close relation between the extent of salvage and the speed of reperfusion is intuitively and theoretically likely. Improvements in reperfusion rates with therapy that would reduce total occlusion time to less than 1 to 3 hours may be particularly relevant. 4.5,8,9,15.37 A recent meta-analysis of published data suggests that 90-minute patency rates are 51% with streptokinase and 70% with t-PA27 and that at 2 to 3 hours the rates are 70% and 73%, respectively. Moreover, a direct comparison of the speed of reperfusion with t-PA or streptokinase (according to noninvasive indices of efficacy) suggested that the mean time to the appearance of signs of reperfusion after the administration of the thrombolytic agent was 72 minutes with streptokinase and 44 minutes (38% reduction in mean reperfusion time) with t-PA38 (PK Shah, personal communication). The relative differences in reperfusion rates were greatest within the first 30 minutes, and 4 hours after the administration of the drug the reperfusion rates were similar. With this finding in mind, it is helpful to reanalyze the data in Figs 2 and 3, assuming that a thrombolytic agent that has a lower speed of reperfusion and 90-minute recanalization rate than those achieved with t-PA results in a maximal difference of 30% less myocardial salvage. (Note that the total reperfusion time is made up only in part of the drug reperfusion time [see "Discussion" and Fig 8] , so the impact of a more rapidly reperfusing regimen on total time to reperfusion may be only of the order of 10% under usual clinical circumstances.) Recalculation of the data suggests that this maximal 30% reduction in the extent of salvage results in an absolute change in salvage from 16% to 11% of the left ventricle and in a final infarct size of 25% of the left ventricle instead of 20% (Fig 3) . This difference in infarct size of only 5% is small and, although perhaps measurable,23 may not result in a significant overall difference in early mortality. A measurable difference in outcome would most likely be detected among therapies with differing reperfusion rates if therapy is begun early and drug delay to reperfusion makes up a substantial part of overall coronary occlusion time and if analysis is restricted to patients with markedly impaired left ventricular function, that is, to those with a large acute myocardial infarction. In this case, the magnitude of salvage, although proportionally the same, would be substantially greater on an absolute scale.
Previous data from the same investigators suggest that a 5% difference in infarct size would translate into only a 2.4% change in ejection fraction. Even if one assumes that the slower-acting drug in question results in 40% less salvage, the numbers are little altered, and the calculated extent of salvage now decreases to 9.6% of the left ventricle with a final infarct size of 26.4% of the left ventricle instead of 20%.
Previous data from patients who did not undergo thrombolysis imply that relatively small changes in ejection fraction could have an impact on late mortality in patients who have poor left ventricular function to begin with.39 Such patients are, however, underrepresented among survivors of trials of thrombolytic therapy, in whom the predischarge ejection fraction tends to approximate 50%. 40, 41 Further evidence is provided by the results of a Mayo Clinic randomized trial that evaluated the effects of t-PA and primary angioplasty on myocardial salvage. 42 The times to reperfusion in the two groups were similar (approximately 4.5 hours), but despite a 93% patency rate after percutaneous transluminal coronary angioplasty (significantly higher than patency rates documented previously with t-PA), there was no difference in myocardial salvage in the two groups. 42 The likelihood of detecting a difference between two biologically active thrombolytic agents administered 3 to 6 hours after the onset of symptoms is further diminished by the heterogeneity of the population in regard to the site of infarction, the presence or persistence of pain, resting myocardial oxygen demands, the time to treatment, and the extent of collaterals.
These data do not negate the benefits of reperfusion on myocardial salvage within the window for salvage commonly encountered in clinical practice. Christian and colleagues36 documented the almost complete lack of salvage among patients with failed reperfusion ( Fig  2) . Nonetheless, these data and the theoretical analysis based on these numbers suggest that the impact of different recanalization rates on final infarct size is minimized by the extent of viable myocardium present and the relative "time independence" of ongoing necrosis at a relatively "late" phase during the evolution of an acute myocardial infarction. This might explain, at least in part, the results of the huge comparative mortality trials involving t-PA, streptokinase, and APSAC and the lack of any substantial difference in ejection fraction in other comparative studies.
Implications ofAnimal Studies
The pivotal studies by Reimer and Jennings4.5 of coronary ligation in the dog emphasized the relatively narrow window for salvage after reperfusion. The bulk of the benefit from reperfusion was achieved within the first hour, although this was favorably modified by an extensive collateral circulation. Bergmann and col-leagues16.43 drew similar conclusions in the dog model of experimental coronary occlusion followed by streptokinase-induced thrombolysis, in which positron emission tomography was used for the assessment of salvage. Although Schaper44 suggested that the collateral circulation in humans is similar to that in a dog, this theory may not apply to many individual patients, particularly those without antecedent angina in whom collaterals are absent and in whom the time during which substantial salvage can be achieved is abbreviated. 45, 46 Supportive Evidence From Clinical Studies
The time-related benefits of thrombolytic therapy are well demonstrated by the randomized clinical trials data base for time-to-treatment cutoff points of 6 hours from onset of symptoms (absolute mortality reductions of 2.9% for treatment in 6 hours or less and 2.1% for treatment in more than 6 hours; 44 035 patients47) and 3 hours (absolute mortality reductions of 3.3% for treatment in 3 hours or less and 2.5% for treatment in more than 3 to 6 hours; 23 150 patients9). Information on mortality risk and treatment benefits within 1 to 2 hours of onset of symptoms is of even greater interest but is still limited ( Table 2 ) and derives primarily from the GISSI8 and ISIS-29 experiences. As the summary of these two trials in Table 2 shows, control patients demonstrated a (reverse) J-shaped relation between time of presentation and mortality. In part, this may be explained by a tendency for sicker patients to seek medical assistance earlier. Table 2 also shows, however, that treatment benefit is clearly greatest (in both relative and absolute terms) when given within the first hour (absolute mortality reduction, 6.5%), is intermediate at 2 to 3 hours (absolute reduction, 2.7%) and 4 to 6 hours (absolute reduction, 2.5%), and is least at 7 to 12 hours (absolute reduction, 1.3%). As a result, mortality rate in treated patients, unlike controls, shows a direct relation with time from symptom onset: those presenting very early (first hour) show the best outcome (8.2% mortality), despite having the worst prognosis if untreated, compared with those treated at 2 to 6 hours (9.6% mortality) or after 6 hours (11.6% mortality). The suggestion of better absolute, as well as relative, outcomes for very early (in less than 1 to 2 hours) therapy is further strengthened by the recent randomized comparisons of early (out-of-hospital) with somewhat delayed (in-hospital) thrombolytic therapy,48.49 as summarized below. Results from the forthcoming GUSTO trial,2425 with its angiographic substudy assessing patency at various time delays from therapy, should also add substantially to this data base.
Relatively few clinical studies have included large numbers of patients with "early reperfusion" (within 1 to 2 hours of symptoms) ( Table 2) . Seventy-two percent of patients in GISSI-2 were randomized within 6 hours, and in ISIS-3, the median time from symptoms to randomization was 4 hours, but in neither trial have the results been broken down according to duration of symptoms.3"9 Those studies that have included these patients reinforce strikingly the benefits of the early administration of therapy. In a study by the National Heart Foundation of Australia Coronary Thrombolysis Group,50 the administration of t-PA within 2 hours of symptoms resulted in an improvement in ejection fraction over placebo of 23%, whereas the difference was 5% in patients treated after 2 to 4 hours (Fig 4) . This 2-hour "cutoff point" was also demonstrated in earlier studies with urokinase. 37 The GISSI-1 trial8 documented that the greatest benefit of streptokinase therapy over placebo was in patients treated within the first 3 hours compared with those treated within 3 to 9 hours. Recalculation of these data, however, demonstrate that the bulk of this mortality reduction was in patients treated within 1 hour ( Fig 5 and Table 2 ). Preliminary data from the TIMI-2 trial46 provide further suggestive evidence. The frequency of a predischarge ejection fraction of more than 55% was significantly greater among patients treated within 1 hour of symptoms than among patients treated later, among whom there was very little difference between those treated within 1 to 2, 2 to 3, and 3 to 4 hours after symptoms (Fig 6) . Mortality rate was directly related to time delays to treatment, and recurrent ischemia was correspondingly more frequent in those treated within the first hour, findings that imply greater initial myocardial salvage with a subsequently greater extent of jeopardized myocardium that is vulnerable to recurrent ischemia ( Fig 6) . Nonrandomized data from Israel51 and Germany52 further emphasize the benefits of earlier reperfusion based on the preservation of an ejection fraction of more than 55% and, by implication, substantially reduced infarct size in patients treated very early (within the first 90 to 120 minutes) in comparison with most patients treated later in the clinical course. 37, 45 These data provide a compelling argument in favor of early reperfusion and its impact on myocardial salvage and further reinforce conclusions drawn from the animal paradigm. Preliminary data from the European Myocardial Infarction Project provide unique insight into the timing of reperfusion and its impact on mortal- ity at a relatively early stage (average of 2 hours) into the clinical course. 49 When the time interval between the prehospital injection of APSAC and hospital administration of the drug was less than 40 minutes, the benefits of prehospital administration on mortality reduction were small. However, once the interval between treatments equated or exceeded 60 minutes, the delayto-hospital arm of the trial was associated with a higher mortality. This finding suggests that the relation between the duration of occlusion and salvage may have a more gradual slope during the first hour of an evolving myocardial infarction. Nonetheless, the realities of clinical practice have resulted in many comparative studies of thrombolytic drugs relatively late in the clinical course (Fig 7) . That salvage occurs at this phase in the evolution of acute infarction is not in doubt, but its extent usually is limited. Ninety-minute patency very early in the clinical course thus may have different implications for salvage than the same end point at a later stage.
Other Beneficial Mechanisms From Acute Reperfusion The concept of time-dependent or time-independent effects of arterial patency on late mortality introduced by Braunwald13 and expanded on by others14-17 is reinforced by the data presented in this discussion. The two mechanisms are not mutually exclusive but rather encompass a spectrum in which the extent of viable, jeopardized myocardium is the primary determinant of the mechanism of benefit.16 P=NS An integral aspect of the concepts incorporated into the structure of the curve in Fig 7 is the recognition that the slope of the curve can be shifted by influences other than time. The rate of necrosis and, therefore, the window for salvage are critically dependent on other factors, such as myocardial oxygen demands, the extent of the coronary collateral circulation, and the duration of or persistence of the complete coronary occlusion (Table 3 ).53,54 As shown in Fig 7, the most likely explanation for the reduction in mortality achieved by early reperfusion is time-dependent myocardial salvage. A time-independent or "less-dependent" mechanism of benefit is also suggested by the composite mortality reduction-versus-time curve (Fig 7) and data from large comparative clinical trials. In many trials, the average time to therapy has been 4 to 6 hours.3'8-12'18-20 The 20% to 30% mortality reductions,'2 comparable among agents given with this relatively long delay after the onset of acute infarction, appear to depend on processes that are less "time dependent." Table 1 suggests mechanisms of these two general processes: the benefit of very early treatment may be derived from timedependent myocardial salvage, and later benefit may be achieved (1) by residual myocardial salvage (such as 
Evidence for Benefits From 'Late' Reperfusion: Pathophysiological Mechanisms
Ventricular remodeling. The mechanisms whereby late reperfusion may influence long-term outcome imply a beneficial effect that is independent of myocardial salvage. This, however, remains conjectural because it has not been proved that salvage (albeit to a limited extent) is not a component of the pathophysiological sequelae of late reperfusion. Brown and colleagues55 found that end-diastolic length increased by 19% to 24% and that end-diastolic volume increased by 42% within 15 minutes of coronary artery ligation in a canine model. Reperfusion after 5.5 hours had no effect on infarct size, but it reduced end-diastolic length to within 1% and end-diastolic volume to within 16% of baseline within 1 hour, whereas acute increases in end-diastolic measurements persisted in the persistent-ligation group. Hoch-1 hr 3hr 6hr 12 hr 12-24 hr FIG 7. Curve of hypothetical relation among mortality reduction (see Table 1 ), the extent of salvage (shaded area under the curve), and the time to reperfusion. In this construct, mortality reduction within the first 1 to 2 hours is primarily due to myocardial salvage. Later reperfusion results in lesser salvage, although mortality is still reduced, perhaps mediated in part through "less timedependent" mechanisms. The slope of the curve can be altered by otherfactors, such as myocardial oxygen demands and the extent of the collateral circulation to the area ofjeopardy. Very early portions of curve (ie, for less than 60 minutes) for rates of myocardial salvage and mortality reduction are undefined by clinical trials and represent conjecture as shown. Relatively constant late benefit function (shown) may be progressively offset (especially for times of more than 12 hours) by an increasing hazard function for thrombolysis (not shown). man and Choo56 observed that chronic infarct expansion in rats was limited by reperfusion achieved too late to reduce infarct size or transmurality compared with permanent coronary artery ligation. Hale and Kloner57 found that late reperfusion in the rat model contributed to improved healing with a thicker scar.
Evidence for benefits of reperfusion unrelated to myocardial salvage also is accumulating in patients. Jeremy and colleagues58 found that spontaneous reperfusion (within 7 to 10 days) prevented left ventricular dilation at 1 month in contrast to patients with persistent occlusion. Touchstone and colleagues59 found echocardiographic infarct expansion exclusively in patients who did not achieve coronary patency. In the GISSI-1 study, treatment (given at a mean of 6 hours) did not improve global ejection fraction measured echocardiographically, but convalescent end-systolic and end-diastolic volumes and the extent of regional wall motion abnormality were reduced in the streptokinase-treated group compared with controls.60 In a preliminary analysis of an angiographical study, Hirayama and colleagues61 found improvement in both systolic function (increased ejection fraction) and diastolic remodeling (reduced end-diastolic volume) in patients achieving early thrombolytic reperfusion compared with patients who remained occluded. Those achieving later (8 hours or more) reperfusion did not have an improvement in ejection fraction but did achieve reductions in end-diastolic volume almost comparable to those in patients treated earlier. Observations of the TIMI-2 group,62 relating ejection fraction to mortality risk, also suggest mechanisms of thrombolysis benefit that are unrelated to salvage; in their experience, a reduction in mortality was observed after thrombolysis compared with untreated, historical control patients at comparable levels of depressed ejection fraction.
Electrical stability. There appears to be a real and extraordinary effect of a patent infarct-related artery on electrical stability. In a small study of patients with left ventricular aneurysms, Sager and colleagues63 were able to induce ventricular tachycardia at electrophysiological study in 88% of patients who did not receive thrombolytic therapy but in only 8% who were treated with thrombolytics. In a substudy of 87 patients in the ISIS-2 trial,M ventricular tachycardia in the postinfarction pe-riod was inducible in 17% of patients treated with placebo but in none in the streptokinase arm. Several series have documented a reduction in the incidence of late potentials on the signal-averaged ECG in patients receiving acute reperfusion therapy,65-67 and this appears to be independent of changes in ejection fraction.65, 66 The mechanisms whereby reperfusion favorably alters the electrical milieu independent of any effect on myocardial salvage are speculative and probably multifactorial, but an interaction between changes in ventricular volume and the electrophysiological substrate for reentry should not be discounted."
Time-independent salvage. Recent evidence raises the intriguing and tantalizing possibility that viable "hibernating" myocardium without clinical or overt evidence of ischemia may exist in patients with Q wave infarctions and severe stenoses of the infarct-related artery.69-71 Moreover, the use of myocardial contrast echocardiography has suggested that collateral flow within the myocardium in humans after acute myocardial infarction is more extensive than previously suggested and that it may play an important functional role in many patients. 72 The possibility that viable myocardium may exist among infarction survivors without clinical evidence of ischemia in the area supplied by a stenotic infarct-related artery has major implications for the potential of late reperfusion to be of benefit even days or weeks after infarction (Fig 7) .69,71,73 Fig 7 may underestimate the extent of viable, salvageable myocardium during the late (6 to 24 hours) and very late (more than 24 hours) phases of reperfusion. Further quantitative studies are needed.
Improving Outcome by Limiting Occlusion Time Delays in Initiating Thrombolytic Therapy
A review of Fig 7 suggests that if outcome is to be improved over current levels, the time from symptoms to reperfusion (total occlusion time) must be substantially reduced. Approaches to achieving earlier reperfusion include development of (1) more rapidly acting and efficient thrombolytic regimens and (2) more efficient strategies of thrombolytic application (reducing "symptom-to-needle time"). The quest to develop improved thrombolytic regimens has attracted much attention. Efforts have been directed at testing modified (eg, APSAC versus streptokinase, prourokinase versus urokinase, mutant and chimeric t-PA versus native t-PA) and combined thrombolytic drug regimens (eg, t-PA and urokinase in Thrombolysis in Acute Myocardial Infarction [TAMI-5], streptokinase and t-PA in GUSTO, t-PA and APSAC in TIMI-4).78 However, "needle-to-reperfusion time" typically is only a small percentage of the total symptom-to-perfusion time (Fig 8) . Once the drug is administered, approximately 45 minutes is required to achieve reperfusion in 50% or more of patients in whom lysis is achieved. 18, 77 Delays to thrombolytic reperfusion are substantial and are key factors to focus on in efforts to improve thrombolytic strategies (Fig 8) . Patient delays in seeking medical assistance may average about 50 minutes, but they are extremely variable and complex.2 Increasing patient delays have been related to several factors, including patient denial; mistaking symptoms for more benign conditions; being alone, more elderly, or less self-sufficient; or attempting to contact a personal physician. Paradoxically, prodromal symptoms or a history of previous angina or myocardial infarction is not associated with a reduction in average delay. Attempts to reduce patient delays have met with limited success to date, but this factor deserves continued attention.
Transportation delays vary depending on the patient's distance from a health care facility and the availability and training of local paramedic and ambulance systems. Compounding this variability is the fact that fewer than half of patients with probable acute myocardial infarction use paramedic systems for transportation, even in model areas such as Seattle.74 For patients who use these systems, approximate 15-minute intervals may be used for call to 911-to-patient, on-site, and site-to-hospital intervals during a typical transport run (45-minute total). Only small improvements in transport time can be expected in efficiently run systems, but increasing use of these systems by patients with chest pain is a worthy goal.
In-hospital delay ("door-to-needle time") is the largest single component of delayabout 40% of the totaland is the most amenable to modification.75,76 After drug administration, the time to reperfusion is about 45 minutes for standard drug regimens.77 Given that needle-to-reperfusion time is less than 20% of the total time, use of more efficient thrombolytic regimens is likely to have only a modest impact on overall outcome. A more rapidly acting thrombolytic regimen may be useful for circumstances in which time-dependent mechanisms are most operative (ie, within 1 to 2 hours of symptom onset) and when treatment leads to a significant reduction in symptom-to-reperfusion time, not just needle-to-reperfusion time.
The most promising approach to improving the efficacy of thrombolysis is to treat the patient earlier. The emergency department has emerged as the preferred place to initiate thrombolytic therapy, as emphasized in the recent joint American College of Cardiology/American Heart Association Task Force Report on the treatment of acute myocardial infarction.79 In the Minnesota experience, 35 minutes was saved by moving the place of initiation of therapy from the coronary care unit to the emergency department. 80 The Virginia Thrombolytic Study Group81 found that urban hospital location, teaching hospital status, a high case volume of acute myocardial infarction, stocking of the drug in the emergency department, and the decision to treat by an emergency physician were significant factors correlating with reduced hospital delay to therapy. The use of a simplified (bolus) regimen also resulted in shorter drug processing and total hospital time than a more complex (infusion) regimen of thrombolytic therapy. Prehospital Versus In-Hospital Initiation of Thrombolytic Therapy Intuitively, prehospital initiation of thrombolytic therapy is the most promising approach to reducing the overall time to therapy in patients seeking paramedic transport, but it is fraught with medical, legal, and cost concerns as well as the extent of general applicability to patients with acute myocardial infarction. Given these concerns, the benefits of prehospital therapeutic strategies should be demonstrated by clinical trials before independent use can be recommended. Two important trials have been completed, and preliminary re'sults have been presented. 48, 49 In the randomized Seattle Myocardial Infarction Triage and Intervention (MITI) study,48 cardiac function and infarct size were assessed in 360 patients who received either in-field or in-hospital treatment with t-PA. Although the effect of treatment assignment was not significant, both groups received therapy at a very early time (median of about 90 minutes after symptom onset), and the time savings for the prehospital strategy per se was small (about 30 minutes). Of note, treatment in less than 70 minutes was found to result in a distinct advantage in ejection fraction outcome (by 4%), infarct size (by 6.3% of the left ventricle), and mortality. 20`T1 radionuclide-determined infarct size was negligible (0% to 1% of the left ventricle) in 39% and negligible to small (10% or less of the left ventricle) in 75% of patients, whereas in historically controlled studies from the same institutions these values were approximately 4% to 12% and 34% to 46% of patients, respectively. 48 The larger European Myocardial Infarction Project (EMIP)49 randomized 5454 patients to in-field versus in-hospital treatment with APSAC and assessed mortality outcome. Patients were treated somewhat later in-field in EMIP (at about 2 hours) than in MITI (about 1 hour), but about 1 hour was saved by in-field treatment compared with in-hospital therapy. The EMIP study, truncated in size because of funding problems, nonetheless showed 17% (Pc.04) and 13% reductions in cardiac and total mortality at 1 month.
Summary
Significant and substantial beneficial effects may be realized for ejection fraction, infarct size, and mortality by decreasing the time from symptoms to therapy, especially when therapy is given within 60 to 90 minutes. However, independent effects of prehospital therapy are more difficult to show (probably because of the overlap in treatment times in the two strategy groups and because of the short transport and very short "door-to-needle times" -less than 20 minutes) in the hospital-treated patients. A reasonable and conservative interim goal for many centers, based on this experience, is to administer therapy in the emergency department but to set a goal for a door-to-needle time of less than 30 minutes, aided by a system of prehospital evaluation, including ECG.
Implications for Clinical Practice and Trials
A recent analysis demonstrated that the time to reperfusion (according to noninvasive indices) with streptokinase was, on average, 28 minutes later than that with t-PA. 38 The relevance of this observation must be placed within the context that the drug is, on average, administered within 3 to 4 hours of symptoms in most studies (Fig 7) .
The focus of the debate thus should shift more toward the more rapid administration of a thrombolytic agent and away from the relative merits of one agent over another. The GUSTO trial will, in all likelihood, resolve the controversy regarding the administration of heparina valid and important issue. The results of this trial in subsets of patients treated within the first 1 to 4 hours of symptoms will be crucial, as will be the data from the angiographic substudy. Differences in 90-minute recanalization rates between the two drugs for relatively "old" clots may not be the same as for "fresh" clots; evidence suggests that although the efficacy of t-PA is time-independent, streptokinase, urokinase, and anistreplase achieve higher early patency rates in patients treated earlier after the onset of symptoms.'5,18,24,77,82 A direct comparison among drugs administered within 1 to 2 hours of symptoms may not be feasible with mortality as an end point given the very low mortality rate of patients treated this early, but other end points such as patency, infarct size, and myocardial salvage would still be of interest.
Conclusions
The era of acute reperfusion is in its third decade. Based on sound pathophysiological principles, widespread national and international interest and collabo-ration83 have demonstrated beyond a doubt the impressive impact of this form of therapy on the outcome of acute myocardial infarction.
The earlier that reperfusion therapy is initiated, the greater are the benefit and the extent of salvage. Nonetheless, "relatively late" sustained reperfusion also results in significant salvage compared with the results in patients with persistently occluded vessels. Moreover, effects of the open artery, independent of salvage, on ventricular remodeling and electrical stability remain an intriguing but increasingly plausible mechanism whereby reperfusion may have an added beneficial effect on early and late outcomes. However, newer techniques of documenting myocardial salvage should be applied to reevaluate whether and to what extent these late benefits are truly independent of myocardial salvage. The controversy engendered by the discrepancy between mortality data and recanalization rates among different but biologically active agents may be explicable, at least in part, by the timing of drug administration in most clinical studies and should not cast doubt on the rationale for reperfusion therapy and the principles for its use based on animal studies. The open-artery hypothesis modifies and expands on the original paradigm, but there is no need for it to be abandoned.
The impetus in the 1990s will be on the approaches to deliver reperfusion therapy more promptly and effectively and to a wider population of patients. The prevention of reocclusion with anticoagulants and platelet inhibitor therapies remains of pivotal importance. The development of thrombolytic drugs capable of more effective and rapid clot lysis should be encouraged but administration of treatment to the widest group of patients who are likely to benefit.
